GoodRx (GDRX) Q4 2025 earnings review
Pharma Direct Booms, But Core Prescription Bleed Forces a 2026 Reset
GoodRx is a tale of two deeply diverging businesses. Pharma Direct (formerly Manufacturer Solutions) is accelerating rapidly, surging 58% YoY in Q4 to $44.4M. However, the core Prescription Transactions engine is collapsing, falling 14% YoY in Q4. The root cause is a devastating 20% YoY drop in Monthly Active Consumers (MACs), plummeting from 6.6 million to 5.3 million due to Rite Aid closures and integrated savings program (ISP) volume reductions. Management has officially called for a reset, issuing FY26 guidance that projects a reversal in both top-line and bottom-line growth. The transition toward a direct-to-consumer (D2C) pharma model is working, but it simply isn't large enough yet to offset the structural retail pharmacy headwinds.
🐂 Bull Case
The rebranded Pharma Direct segment grew 41% for the full year and accelerated to 58% in Q4. It proves GoodRx has immense pricing power and ROI validation for pharmaceutical manufacturers moving toward direct-to-consumer access.
Despite top-line pressures, GoodRx generated $167.9M in operating cash flow in FY25, enabling the company to aggressively repurchase 48.9 million shares for $217.4M, retiring over 10% of its outstanding float.
🐻 Bear Case
Monthly Active Consumers (MACs) fell from 6.6 million in 24Q4 to 5.3 million in 25Q4. The Rite Aid bankruptcy and PBM partner shifts are doing permanent damage to the traditional aggregator model.
After expanding Adjusted EBITDA to $270.5M in 2025, management's FY26 guidance of '>$230M' implies a brutal margin compression and a reversal of profitability as the company attempts to restructure its operations.
⚖️ Verdict: 🔴
Bearish. While Pharma Direct is a phenomenal asset, the company is shrinking overall. A 20% loss in the active consumer base and guidance for an earnings contraction in 2026 show that the core business model is under severe structural threat.
Key Themes
Pharma Direct: The New Growth Engine
Pharma Direct (formerly Manufacturer Solutions) is accelerating dramatically. Q4 revenue hit $44.4 million, up 58% YoY. For the full year, it grew 41% to $151.4 million. The strategy of moving beyond simple advertising to secure high-ROI, point-of-sale cash buy-downs with major manufacturers (like Amgen and Novo Nordisk) is working. This segment is rapidly becoming the most valuable piece of GoodRx's portfolio.
The Collapse of Monthly Active Consumers (MACs)
The bleeding in the core marketplace is severe. MACs have been steadily decelerating, ending Q4 at 5.3 million, down from 6.6 million a year ago. Management cites Rite Aid store closures and the erosion of an Integrated Savings Program (ISP) with a key PBM partner. Management is attempting to 'reassess the MAC metric' entirely, which is a classic red flag when a legacy KPI turns permanently negative.
Reversing Profitability for 2026
Cost discipline masked the core revenue decay in 2025, driving Adjusted EBITDA up to $270.5M (33.9% margin). However, this trend is violently reversing. FY26 guidance projects Adjusted EBITDA to fall to '>$230M'. This implies a significant deleverage event, likely driven by high marketing costs required to stabilize the MAC bleed while high-margin legacy ISP revenues disappear.
Subscription Pivot to Condition-Specific Offerings
While overall subscription revenue dropped 3% for the full year due to the sunset of the Kroger Savings Club, Q4 saw a stable trajectory with $21.6M in revenue (+4% YoY). This stabilization is being driven by a strategic pivot away from generic savings clubs toward high-intent, condition-specific subscriptions (e.g., erectile dysfunction, hair loss, weight loss) which generate stickier, recurring revenue.
Macro Tailwinds from Federal Transparency Initiatives
Management continues to view federal push for price transparency (such as the proposed TrumpRx.gov platform and Most Favored Nation pricing) as a structural tailwind. As government pressure forces manufacturers to create more direct-to-consumer (D2C) cash offerings, GoodRx is perfectly positioned as the API and transaction layer to process these discounts.
Other KPIs
Decelerating from $183.9 million in FY24. Despite lower cash generation, the absolute number remains highly robust for a company of this size, proving the underlying cash-conversion profile of the platform is intact even amid top-line disruption.
GoodRx bought back 48.9 million shares of Class A common stock in 2025. This aggressive capital return strategy signals management's belief that shares are undervalued, though it leaves only $72.9 million in authorized capacity heading into a challenging 2026.
Guidance
Reversing. After achieving 1% growth in FY25 ($796.9M), revenue is guided to contract by 2% to 6% in FY26. This explicitly contradicts earlier narratives from Q3 calls where management targeted overcoming 2025's 'perfect storm' to achieve expansion in 2026.
Reversing. Down drastically from the $270.5M achieved in FY25. This guidance floor implies an Adjusted EBITDA margin contraction from nearly 34% down to approximately 30%, reflecting the severe loss of high-margin prescription transaction volumes.
Key Questions
The Floor for MACs
With MACs dropping from 6.6M to 5.3M in a single year, where is the natural floor? How much of the remaining 5.3M base is exposed to further PBM network shifts?
Margin De-leverage Details
The drop from $270M to $230M in Adjusted EBITDA implies severe negative operating leverage. Is this entirely due to mix shift away from legacy ISP revenues, or are you planning massive brand reinvestments in 2026?
TrumpRx.gov Monetization
While you cite TrumpRx.gov as a tailwind, how exactly does GoodRx monetize API integrations with a federal repository? Will this cannibalize your own native search traffic?
KPI Shifting
You mentioned 'reassessing the Monthly Active Consumers metric.' When a company changes its primary KPI during a period of decline, it alarms investors. What metric do you plan to replace it with, and will you provide historical restatements?